The Use of Molecular Breast Imaging to Assess Response in Women Undergoing Neoadjuvant Therapy for Breast Cancer

Abstract

Measurements of tumor size by MBI and T/B ratios are limited in their predictive value regarding the pathologic extent of residual disease in women treated with NT for breast cancer. Alternate tumor-specific radiopharmaceuticals should be evaluated to provide information to improve planning and monitoring of breast cancer treatment.